1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sino Biopharmaceutical : Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$9.3 From HK$8.97, Keeps at Buy

03/30/2021 | 05:11am EDT


© MT Newswires 2021
All news about SINO BIOPHARMACEUTICAL LIMITED
06:39aChina Accepts Sino Biopharm's Marketing Application for Cancer Drug
MT
01:41aSino Biopharm Buys Back $278 Million of Euro-Denominated Bonds
MT
05/23Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor I..
CI
05/23Sino Biopharm Repurchases $168 Million of Euro-Denominated Bonds
MT
05/19Sino Biopharm Unit to Purchase Tumor Inhibitor of Danish Biotech Firm Symphogen
MT
05/11Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally
MT
05/06UBS Adjusts Sino Biopharmaceutical's Price Target to HK$8 From HK$11.6, Keeps at Buy
MT
05/05Sino Biopharm Repurchases $86.5 Million of Euro-Denominated Bonds
MT
04/25Sino Biopharmaceutical Signs License Deal for Hepatitis, Diabetes Drugs
MT
04/20Sino Biopharm Gets Clearance to Start China Clinical Trial of Anti-Tumor Drug
MT
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Financials
Sales 2022 37 731 M 4 807 M 4 807 M
Net income 2022 6 584 M 839 M 839 M
Net cash 2022 6 140 M 782 M 782 M
P/E ratio 2022 12,4x
Yield 2022 1,63%
Capitalization 79 179 M 10 087 M 10 087 M
EV / Sales 2022 1,94x
EV / Sales 2023 1,41x
Nbr of Employees 25 579
Free-Float 52,2%
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | 1177 | KYG8167W1380 | MarketScreener
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 4,24 HKD
Average target price 8,21 HKD
Spread / Average Target 93,6%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Jia yin Ma Group Chief Financial Officer
Theresa Tse Chairman
Mao Li Chief Medical Officer
Zheng Fei Lu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-21.06%10 253
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY9.55%272 388
ABBVIE INC.9.33%261 585